- Home
- MTEK vs CVKD Comparison
MTEK vs CVKD Comparison
Compare MTEK & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEK
- CVKD
- Stock Information
- Founded
- MTEK 2008
- CVKD 2022
- Country
- MTEK Israel
- CVKD United States
- Employees
- MTEK N/A
- CVKD N/A
- Industry
- MTEK
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- MTEK
- CVKD Health Care
- Exchange
- MTEK Nasdaq
- CVKD Nasdaq
- Market Cap
- MTEK 17.6M
- CVKD 20.8M
- IPO Year
- MTEK 2022
- CVKD 2023
- Fundamental
- Price
- MTEK $4.42
- CVKD $12.96
- Analyst Decision
- MTEK
- CVKD Strong Buy
- Analyst Count
- MTEK 0
- CVKD 2
- Target Price
- MTEK N/A
- CVKD $46.00
- AVG Volume (30 Days)
- MTEK 337.8K
- CVKD 64.9K
- Earning Date
- MTEK 12-31-2024
- CVKD 11-07-2024
- Dividend Yield
- MTEK N/A
- CVKD N/A
- EPS Growth
- MTEK N/A
- CVKD N/A
- EPS
- MTEK N/A
- CVKD N/A
- Revenue
- MTEK $6,967,508.00
- CVKD N/A
- Revenue This Year
- MTEK N/A
- CVKD N/A
- Revenue Next Year
- MTEK N/A
- CVKD N/A
- P/E Ratio
- MTEK N/A
- CVKD N/A
- Revenue Growth
- MTEK 246.50
- CVKD N/A
- 52 Week Low
- MTEK $1.01
- CVKD $5.40
- 52 Week High
- MTEK $5.31
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- MTEK 83.63
- CVKD 47.69
- Support Level
- MTEK $2.11
- CVKD $10.65
- Resistance Level
- MTEK $3.32
- CVKD $12.25
- Average True Range (ATR)
- MTEK 0.49
- CVKD 1.50
- MACD
- MTEK 0.18
- CVKD -0.12
- Stochastic Oscillator
- MTEK 73.19
- CVKD 45.85
About MTEK Maris-Tech Ltd.
Maris Tech Ltd is a provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.